ANI Pharmaceuticals
ANIP
121 hedge funds and large institutions have $194M invested in ANI Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 20 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 123 → 121 (-2)
32% less capital invested
Capital invested by funds: $285M → $194M (-$91.5M)
36% less call options, than puts
Call options by funds: $4.58M | Put options by funds: $7.19M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
Top Sellers
| 1 |
SAM
Senzar Asset Management
New York
|
-$7.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.06M |
| 3 |
First Manhattan
New York
|
-$6.96M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$5.58M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.84M |
ANIP Hedge Fund Activity: Q1 2016 in Review
121 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2016, worth a combined $194M — down 32% from $285M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ANIP and 19 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 45 added.
The largest buyer was Perceptive Advisors, adding an estimated $3.43M. The largest seller was Senzar Asset Management, cutting an estimated $7.8M.
- 121 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2016, down from 123 in Q4 2015.
- Funds reported $194M of ANI Pharmaceuticals stock for Q1 2016, down 32% quarter-over-quarter.
- 19 funds opened new ANI Pharmaceuticals positions in Q1 2016 and 20 closed out, a net change of -1 holder.
- The largest ANI Pharmaceuticals buyer in Q1 2016 was Perceptive Advisors, an estimated $3.43M added.
- The largest ANI Pharmaceuticals seller in Q1 2016 was Senzar Asset Management, an estimated $7.8M sold.
Based on aggregated 13F filings for Q1 2016.